These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

593 related articles for article (PubMed ID: 25716300)

  • 1. Neurodegenerative diseases and therapeutic strategies using iron chelators.
    Ward RJ; Dexter DT; Crichton RR
    J Trace Elem Med Biol; 2015; 31():267-73. PubMed ID: 25716300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential application of iron chelators for the treatment of neurodegenerative diseases.
    Hider RC; Roy S; Ma YM; Le Kong X; Preston J
    Metallomics; 2011 Mar; 3(3):239-49. PubMed ID: 21344071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron chelation in the treatment of neurodegenerative diseases.
    Dusek P; Schneider SA; Aaseth J
    J Trace Elem Med Biol; 2016 Dec; 38():81-92. PubMed ID: 27033472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron: a new target for pharmacological intervention in neurodegenerative diseases.
    Whitnall M; Richardson DR
    Semin Pediatr Neurol; 2006 Sep; 13(3):186-97. PubMed ID: 17101458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review on iron chelators as potential therapeutic agents for the treatment of Alzheimer's and Parkinson's diseases.
    Singh YP; Pandey A; Vishwakarma S; Modi G
    Mol Divers; 2019 May; 23(2):509-526. PubMed ID: 30293116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The transition metals copper and iron in neurodegenerative diseases.
    Rivera-Mancía S; Pérez-Neri I; Ríos C; Tristán-López L; Rivera-Espinosa L; Montes S
    Chem Biol Interact; 2010 Jul; 186(2):184-99. PubMed ID: 20399203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia.
    Calabrese V; Lodi R; Tonon C; D'Agata V; Sapienza M; Scapagnini G; Mangiameli A; Pennisi G; Stella AM; Butterfield DA
    J Neurol Sci; 2005 Jun; 233(1-2):145-62. PubMed ID: 15896810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.
    Zheng H; Weiner LM; Bar-Am O; Epsztejn S; Cabantchik ZI; Warshawsky A; Youdim MB; Fridkin M
    Bioorg Med Chem; 2005 Feb; 13(3):773-83. PubMed ID: 15653345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Green tea catechins as brain-permeable, non toxic iron chelators to "iron out iron" from the brain.
    Mandel S; Weinreb O; Reznichenko L; Kalfon L; Amit T
    J Neural Transm Suppl; 2006; (71):249-57. PubMed ID: 17447435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, physical-chemical characterisation and biological evaluation of novel 2-amido-3-hydroxypyridin-4(1H)-ones: Iron chelators with the potential for treating Alzheimer's disease.
    Gaeta A; Molina-Holgado F; Kong XL; Salvage S; Fakih S; Francis PT; Williams RJ; Hider RC
    Bioorg Med Chem; 2011 Feb; 19(3):1285-97. PubMed ID: 21236688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron involvement in neural damage and microgliosis in models of neurodegenerative diseases.
    Shoham S; Youdim MB
    Cell Mol Biol (Noisy-le-grand); 2000 Jun; 46(4):743-60. PubMed ID: 10875437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iron chelation and neuroprotection in neurodegenerative diseases.
    Li X; Jankovic J; Le W
    J Neural Transm (Vienna); 2011 Mar; 118(3):473-7. PubMed ID: 21161300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dysregulation of glutathione homeostasis in neurodegenerative diseases.
    Johnson WM; Wilson-Delfosse AL; Mieyal JJ
    Nutrients; 2012 Oct; 4(10):1399-440. PubMed ID: 23201762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ironing out the Brain.
    Ward RJ; Crichton RR
    Met Ions Life Sci; 2019 Jan; 19():. PubMed ID: 30855105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chelating agents for neurodegenerative diseases.
    Ward RJ; Dexter DT; Crichton RR
    Curr Med Chem; 2012; 19(17):2760-72. PubMed ID: 22489724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Green tea catechins as brain-permeable, natural iron chelators-antioxidants for the treatment of neurodegenerative disorders.
    Mandel S; Amit T; Reznichenko L; Weinreb O; Youdim MB
    Mol Nutr Food Res; 2006 Feb; 50(2):229-34. PubMed ID: 16470637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ageing, neuroinflammation and neurodegeneration.
    Ward RJ; Dexter DT; Crichton RR
    Front Biosci (Schol Ed); 2015 Jun; 7(1):189-204. PubMed ID: 25961695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological metals and metal-targeting compounds in major neurodegenerative diseases.
    Barnham KJ; Bush AI
    Chem Soc Rev; 2014 Oct; 43(19):6727-49. PubMed ID: 25099276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel therapeutic approach for neurodegenerative pathologies: multitarget iron-chelating drugs regulating hypoxia-inducible factor 1 signal transduction pathway.
    Weinreb O; Amit T; Mandel S; Youdim MB
    Neurodegener Dis; 2012; 10(1-4):112-5. PubMed ID: 22156453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.